ArticleJournal of biochemical and molecular toxicology2026
Luteolin Alleviates Axitinib-Induced Cardiomyocyte Apoptosis in Mice.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Axitinib, a tyrosine kinase inhibitor (TKI), is associated with a risk of cardiotoxicity in clinical practice. However, its underlying toxicological mechanisms remain unclear, and effective cardioprotective strategies are lacking. This study aims to investigate the mechanisms of axitinib-induced cardiac injury and evaluate the protective effects of luteolin. In this study, C57BL/6 mice were randomly divided into four groups: Control, Axitinib, Axitinib + Luteolin, and Luteolin alone. Ventricular systolic function (EF/FS/LVEDD/LVESD) was evaluated by echocardiography. Serum cardiac troponin T (cTnT) levels were measured to assess cardiotoxicity. Histopathological changes were observed via HE and Masson's trichrome staining. Myocardial apoptosis was quantified using TUNEL staining, and apoptosis-related proteins (Bax/Bcl2) were analyzed by Western blot. Reactive oxygen species (ROS) accumulation was evaluated using DHE staining. The results showed that compared with the control group, axitinib did not significantly alter echocardiographic parameters but significantly elevated serum cTnT levels, indicating subclinical cardiotoxicity. Furthermore, axitinib induced notable histopathological changes, promoted aberrant ROS accumulation, upregulated the Bax/Bcl2 ratio, and triggered cardiomyocyte apoptosis. Co-administration of luteolin significantly reduced ROS levels, restored the Bax/Bcl2 balance, and effectively alleviated axitinib-induced cardiotoxicity and apoptosis. In conclusion, axitinib induces subclinical cardiac injury by promoting ROS generation and disrupting the Bax/Bcl2 balance, thereby activating cardiomyocyte apoptosis. Luteolin exerts significant cardioprotective effects by suppressing ROS accumulation and rectifying apoptotic pathway dysregulation, providing a promising novel strategy for the prevention and treatment of targeted therapy-induced cardiotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.